Class summary at a glance.

Every drug in the Partial Cholinergic Nicotinic Agonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $270.7Mcombined across class
Total Rx claims: 995K420K unique beneficiaries
Generic mfrs (active): 20across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Varenicline

Brand: CHANTIX · 995K Part D claims (CY24) · 420K beneficiaries · First FDA approval: 2006-05-10

20 generic mfrs 1 plans require PA

Low NADAC$0.373

→

Avg plan cost$2.01

Part D spend $270.7M 5× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.